WSO.B Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
WSO.B is not a good buy right now. With the stock at $384.9, Wall Street’s latest targets cluster around ~$370 (below the current price) and ratings are mostly Neutral, while the technical setup is near resistance with fading momentum and the pattern-based forecast flags downside risk over the next month. For an impatient buyer, the risk/reward at this level is unattractive—this is a HOLD/avoid new entry until a pullback closer to support ($374 or ~$369) or a clear post-earnings breakout.
Intellectia Proprietary Trading Signals
Price is sitting just above the pivot (Pivot 381.66) and below near-term resistance (R1 389.67; R2 394.62). RSI(6) at ~64.7 is neutral-to-slightly-warm (not oversold), suggesting limited immediate “dip-buy” edge. MACD histogram is positive (0.311) but positively contracting, implying bullish momentum is weakening rather than strengthening. Moving averages are converging, consistent with consolidation rather than a strong trend. Pattern-based projection adds caution: ~80% chance of -1.47% next day, +1.64% next week, but -6.27% next month—skewing the medium-term bias lower unless price breaks and holds above ~390–395.
Event-driven: Earnings on 2026-02-17 (pre-market) could reset expectations if HVAC demand/pricing or guidance surprises to the upside.
Margins: Latest quarter showed gross margin expansion (+5.00% YoY), a constructive sign if it persists.
News flow: Giverny Capital initiated a new position in Watsco (2026-01-29), a modest sentiment positive from an institutional portfolio update.
Analyst targets vs price: Recent targets around ~$370 are below the current ~$385, capping near-term upside in consensus framing.
Fundamentals: 2025/Q3 showed declines in revenue, net income, and EPS (all down mid-single digits YoY), indicating soft growth.
Technical positioning: Price is close to resistance (~390–
with contracting MACD momentum—risk of rejection/pullback.
Quant/pattern outlook: Similar-pattern analysis points to a negative 1-month expectation (-6.27%).
Latest reported quarter: 2025/Q3. Revenue fell to ~$2.067B (-4.31% YoY), net income fell to ~$150.9M (-5.19% YoY), and EPS fell to ~$3.98 (-5.69% YoY). The notable bright spot was gross margin improvement to ~27.52% (+5.00% YoY), suggesting better pricing/mix or cost control, but the top-line and earnings trend was still negative YoY going into the upcoming QDEC 2025 report (2026-02-17).
Recent trend: predominantly Neutral with price targets stepping down and clustering near ~$370. Mizuho cut PT to $370 (Neutral). UBS resumed Neutral at $370 (down from $390) and previously cut to $390 from $425. JPMorgan raised to $370 from $360 (still Neutral). Wolfe is the outlier with Underperform and a lower $349 target.
Wall Street “pros” view: margin resilience and potential for growth broadening into 2026 (rate cuts/help to demand) are supportive. Wall Street “cons” view: limited near-term catalyst expectations into Q4/QDEC reporting, uneven sector terrain, and valuation/price already above many targets—leading to a cautious/neutral stance overall.
Influential/political trading: No recent congress trading data available; hedge funds and insiders show Neutral/no significant recent trend.
